Журнал «Боль. Суставы. Позвоночник» Том 14, №3, 2024
Вернуться к номеру
Українські рекомендації щодо профілактики та лікування глюкокортикоїд-індукованого остеопорозу
Авторы: Григор’єва Н.В. (1), Коваленко В.М. (2), Корж М.О. (3, 4), Тронько М.Д. (5), Головач І.Ю. (6), Дєдух Н.В. (1), Рекалов Д.Г. (2), Страфун С.С. (7), Сміян С.І. (8), Голубовська О.А. (9), Дзюблик Я.О. (10), Харченко Н.В. (11), Проценко Г.О. (2), Гарміш О.О. (2), Орленко В.Л. (5), Климовицький Ф.В. (12), Мусієнко А.С. (1), Карасевська Т.А. (9), Українська асоціація остеопорозу
(1) - Державна установа «Інститут геронтології імені Д.Ф. Чеботарьова Національної академії медичних наук України», м. Київ, Україна
(2) - Державна установа «Національний науковий центр «Інститут кардіології, клінічної та регенеративної медицини імені академіка М.Д. Стражеска Національної академії медичних наук України», м. Київ, Україна
(3) - Державна установа «Інститут патології хребта та суглобів імені проф. М.І. Ситенка Національної академії медичних наук України», м. Харків, Україна
(4) - Харківський національний медичний університет Міністерства охорони здоров’я України, м. Харків, Україна
(5) - Державна установа «Інститут ендокринології та обміну речовин імені В.П. Комісаренка Національної академії медичних наук України», м. Київ, Україна
(6) - Клінічна лікарня «Феофанія» Державного управління справами, м. Київ, Україна
(7) - Державна установа «Інститут травматології та ортопедії Національної академії медичних наук України», м. Київ, Україна
(8) - Тернопільський національний медичний університет імені І.Я. Горбачевського Міністерства охорони здоров’я України, м. Тернопіль, Україна
(9) - Національний медичний університет імені О.О. Богомольця Міністерства охорони здоров’я України, м. Київ, Україна
(10) - Державна установа «Національний інститут фтизіатрії і пульмонології імені Ф.Г. Яновського
Національної академії медичних наук України», м. Київ, Україна
(11) - Національний університет охорони здоров’я України імені П.Л. Шупика, м. Київ, Україна
(12) - Донецький національний медичний університет Міністерства охорони здоров’я України,
м. Кропивницький, Україна
Рубрики: Ревматология, Травматология и ортопедия
Разделы: Справочник специалиста
Версия для печати
Резюме
Вступ. Глюкокортикоїд-індукований остеопороз (ГК-ОП) — метаболічне захворювання кісткової тканини, що розвивається внаслідок прийому глюкокортикоїдів (ГК), є однією з найбільш частих причин вторинного остеопорозу, призводить до збільшення ризику малотравматичних переломів, збільшення інвалідизації хворих та їх смертності. Незважаючи на проведені поодинокі дослідження в Україні щодо епідеміології та лікування ГК-ОП, національних рекомендацій щодо його менеджменту до цього часу не було, що й стало підставою для їх створення. Мета дослідження: на основі аналітичного аналізу сучасних літературних джерел розробити національні рекомендації щодо діагностики, профілактики та лікування ГК-ОП задля поліпшення обізнаності медичної спільноти України, поліпшення менеджменту і зменшення соціально-економічного тягаря захворювання. Матеріали та методи. Для розробки рекомендацій була створена група з 18 експертів, провідних українських учених різного фаху. Проведено аналіз сучасних літературних джерел щодо епідеміології, факторів ризику, діагностики, профілактики й лікування ГК-ОП, моніторингу ефективності й безпечності його лікування. Синтез доказів виконано за допомогою системи GRADE, критичну оцінку якості положень рекомендацій проведено за допомогою інструменту AGREE II. Результати. Рекомендації складаються з 12 положень щодо скринінгу, діагностики, профілактики й лікування ГК-ОП. Авторами наголошено на необхідності збільшення обізнаності медичної спільноти України щодо проблеми, а також пацієнтів щодо можливих побічних ефектів ГК, подано особливості клінічної оцінки ризику остеопоротичних переломів у користувачів ГК, а також сучасні й доступні в Україні методи його діагностики та лікування. Висновки. Перші українські рекомендації щодо скринінгу, діагностики, профілактики та лікування ГК-ОП є важливим національним інструментом менеджменту ГК-ОП, який рекомендований Президією Української асоціації остеопорозу до використання в практичній охороні здоров’я лікарями різного фаху.
Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few studies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its management until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.
Ключевые слова
глюкокортикоїд-індукований остеопороз; вторинний остеопороз; рекомендації; діагностика, профілактика, лікуввання
glucocorticoid-induced osteoporosis; secondary osteoporosis; recommendations guideline; diagnosis, prevention, treatment
Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.
Список литературы
1. International Osteoporosis Foundation. About Osteoporosis. Available from: https://www.osteoporosis.foundation/health-professionals/about-osteoporosis. Accessed: 2024.06.30.
2. Povoroznyuk VV, Grygorieva NV, Orlyk TV, Balatska NI, Dzerovich NI, Nishkumai OI. Osteoporosis in the practice of an internist. Kyiv, 2014; 198 p. (in Ukrainian).
3. Kovalenko VM, Garmish OO. Glucocorticoids. Kyiv, 2020; 64 pp. (in Ukrainian).
4. Rekalov DG, Dotsenko SYa, Kulinich RL, etc. Glucocorticoids in rheumatology — NEMO SINE VITIIS EST. Ukrainian Rheumatological Journal. 2023;4(94):23-31. doi: 10.32471/rheumatology.2707-6970.94.18360. (in Ukrainian).
5. WHO. Disorders of bone density and structure. In: International Statistical Classification of Diseases and Related Health Problems 10th Revision; Chapter XIII: Diseases of the musculoskeletal system and connective tissue. M80-M85. Available from: https://icd.who.int/browse10/2019/ en#/M80. Accessed: 2023.06.30.
6. Golovach IY. Glucocorticoid-induced osteoporosis. Kyiv: Medical book, 2019; 240 p. (in Ukrainian).
7. Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018 Dec 27;379(26):2547-2556. doi: 10.1056/NEJMcp1800214. PMID: 30586507.
8. Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab. 2019 Jul;14(4):259-266. doi: 10.1080/17446651.2019.1617131. Epub 2019 May 16. PMID: 31094232.
9. Hayat S, Magrey MN. Glucocorticoid-induced osteoporosis: Insights for the clinician. Cleve Clin J Med. 2020 Jun 30;87(7):417-426. doi: 10.3949/ccjm.87a.19039. PMID: 32605977.
10. Jha SS. Glucocorticoid-Induced Osteoporosis (GIOP). Indian J Orthop. 2023 Nov 29;57 (Suppl 1):181-191. doi: 10.1007/s43465-023-01037-8. PMID: 38107807; PMCID: PMC10721764.
11. Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019 Jun;30(6):1145-1156. doi: 10.1007/s00198-019-04906-x. Epub 2019 Feb 25. PMID: 30805679.
12. Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD. Understanding and Managing Corticosteroid-Induced Osteoporosis. Open Access Rheumatol. 2021 Jul 2;13:177-190. doi: 10.2147/OARRR.S282606. PMID: 34239333; PMCID: PMC8259736.
13. Ma CC, Xu SQ, Gong X, et al. Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. Arch Osteoporos. 2017 Dec;12(1):33. doi: 10.1007/s11657-017-0329-0. Epub 2017 Apr 3. PMID: 28374332.
14. Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M. Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab. 2021 Nov;39(6):1019-1030. doi: 10.1007/s00774-021-01236-z. Epub 2021 Jun 14. PMID: 34125296.
15. Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016 May;27(5):1709-18. doi: 10.1007/s00198-015-3455-9.
16. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6. Erratum in: Arthritis Rheumatol. 2017 Nov;69(11):2246. doi: 10.1002/art.40340. PMID: 28585373.
17. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2023 Dec;75(12):2088-2102. doi: 10.1002/art.42646.
18. Laurent MR, Goemaere S, Verroken C, et al. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. Front Endocrinol (Lausanne). 2022 Jun 9;13:908727. doi: 10.3389/fendo.2022.908727. PMID: 35757436; PMCID: PMC9219603.
19. Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mi–neral Research: 2014 update. J Bone Miner Metab. 2014 Jul;32(4):337-50. doi: 10.1007/s00774-014-0586-6. Epub 2014 May 13. PMID: 24818875.
20. Leipe J, Holle JU, Weseloh C, Pfeil A, Krüger K. German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis. Z Rheumatol. 2021 Dec;80 (Suppl 2):49-63. English. doi: 10.1007/s00393-021-01025-z. Epub 2021 Oct 27. PMID: 34705070.
21. Messina OD, Vidal M, Torres JAM, et al. Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update: This manuscript has been produced under the auspices of the Committee of National Societies (CNS) and the Committee of Scientific Advisors (CSA) of the International Osteoporosis Foundation (IOF). Aging Clin Exp Res. 2022 Nov;34(11):2591-2602. doi: 10.1007/s40520-022-02261-2. Epub 2022 Nov 9. PMID: 36348222.
22. Pereira RMR, Perez MO, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumato–logy (2020). Arch Osteoporos. 2021 Mar 1;16(1):49. doi: 10.1007/s11657-021-00902-z. PMID: 33646403.
23. Briot K, Cortet B, Roux C, et al.; Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO). 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014 Dec;81(6):493-501. doi: 10.1016/j.jbspin.2014.10.0
24. Park SY, Gong HS, Kim KM, et al. Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis. J Bone Metab. 2018 Nov;25(4):195-211. doi: 10.11005/jbm.2018.25.4.195. Epub 2018 Nov 30. PMID: 30574464; PMCID: PMC6288607.
25. Gonzalez-Macias J, Del Pino-Montes J, Olmos JM, Nogues X; en nombre de la Comision de Redaccion de las Guias de Osteoporosis de la SEIOMM. Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014). Rev Clin Esp. 2015;215:515-26.
26. Naranjo Hernández A, Díaz Del Campo Fontecha P, Aguado Acín MP, et al. Recommendations by the Spanish Society of Rheumatology on Osteoporosis. Reumatol Clin (Engl Ed). 2019 Jul-Aug;15(4):188-210. English, Spa–nish. doi: 10.1016/j.reuma.2018.09.004. Epub 2018 Nov 22. PMID: 30470636.
27. Herath M, Langdahl B, Ebeling PR, Milat F. Challenges in the diagnosis and management of glucocorticoid-induced osteoporosis in younger and older adults. Clin Endocrinol (Oxf). 2022 Apr;96(4):460-474. doi: 10.1111/cen.14637.
28. Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD Open 2015;1:e000014. doi: 10.1136/rmdopen-2014-000014.
29. Saag KG. Glucocorticoids in chronic disease: the good, the bad, the bone. Trans Am Clin Climatol Assoc. 2023;133:69-80. PMID: 37701582; PMCID: PMC10493762.
30. Billups SJ, Thai VK, Denkins J, Dettman IC, Rothman MS. Bad to the bones: prescribing of drugs for the prevention and treatment of osteoporosis in patients on chronic glucocorticoids. Arch Osteoporos. 2023 Mar 1;18(1):38. doi: 10.1007/s11657-023-01222-0. PMID: 36856881; –PMCID: PMC9976654.
31. Iki M, Fujimori K, Nakatoh S, et al. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. Bone. 2022 Jul;160:116396. doi: 10.1016/j.bone.2022.116396. Epub 2022 Mar 26. PMID: 35351673.
32. Povoroznyuk VV, Grygorieva NV, Karasevska TA, Dzerovich NI. Bone mineral density and Trabecular Bone Score indices in women with rheumatoid arthritis according to the age and use of glucocorticoids. SM J Orthop. 2017; 3(4):1061s.
33. Romanovsky AV, Orlik TV. Interaction of the–rapy on bone mineral density in male and female patients with rheumatoid arthritis. Ukrainian Medical Journal. 2019;133(5):41-44. doi: 10.32471/umj.1680-3051.133.162723. (in Ukrainian).
34. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/ bmj.39489.470347.AD.
35. Varyvonchyk DV, Hoyda NG, Horbenko GV, et al., authors; Ross G, Novichkova O, editors. Guide for develo–pers of clinical recommendations/medical standards. Kyiv: NICARE; 2006. 166 p. (in Ukrainian).
36. Brouwers MC, Kho ME, Browman GP, et al.; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010 Dec 14;182(18):E839-42. doi: 10.1503/cmaj.090449. Epub 2010 Jul 5. PMID: 20603348; PMCID: PMC3001530.
37. Waljee AK, Rogers MA, Lin P, et al. Short-term use of oral corticosteroids and related harms among adults in the United States: population-based cohort study. BMJ. 2017;357(8101):j1415. doi: 10.1136/bmj.j1415.
38. Laugesen K, Jorgensen JOL, Petersen I, Sorensen HT. Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark. Eur J Endocrinol. 2019;181(3):267-273. doi: 10.1530/EJE-19-0305.
39. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011;50(11):1982-199. doi: 10.1093/rheumatology/ker017.
40. Benard-Laribiere A, Pariente A, Pambrun E, Begaud B, Fardet L, Noize P. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017;7(7):e015905. doi: 10.1136/bmjopen-2017-015905.
41. Bjornsdottir HH, Einarsson ÓB, Gröndal G, Gudbjornsson B. Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users. SAGE Open Med. 2024 Mar 20;12:20503121241235056. doi: 10.1177/20503121241235056. PMID: 38516640; PMCID: PMC10956150.
42. Einarsdottir MJ, Ekman P, Trimpou P, Olsson DS, Johannsson G, Ragnarsson O. High prescription rate of oral glucocorticoids in children and adults: a retrospective cohort study from western Sweden. Clin Endocrinol (Oxf). 2020;92(1):21-28. doi: 10.1111/cen.14114.
43. Díez-Pérez A, Hooven FH, Adachi JD, et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone. 2011 Sep;49(3):493-8. doi: 10.1016/j.bone.2011.05.007. Epub 2011 May 14. PMID: 21605715; PMCID: PMC4897770.
44. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-65. doi: 10.1517/14740338.2016.1140743. Epub 2016 Feb 6. PMID: 26789102.
45. Rekalov D, Golovach I, Briner I, et al. Glucocorticoids in rheumatology: myths vs. reality. MOJ Orthop Rheumatol. 2024;16(1):17-23. doi: 10.15406/mojor.2024.16.00657.
46. Gado M, Baschant U, Hofbauer LC, Henneicke H. Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front Endocrinol (Lausanne). 2022 Mar 31;13:835720. doi: 10.3389/fendo.2022.835720.
47. Rossini M, Viapiana O, Vitiello M, et al. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo. 2017 May 22;69(1):30-39. doi: 10.4081/reumatismo.2017.922. PMID: 28535619.
48. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000 Jun;15(6):993-1000. doi: 10.1359/jbmr.2000.15.6.993. PMID: 10841167.
49. Trijau S, de Lamotte G, Pradel V, et al. Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open. 2016 Jul 7;2(2):e000249. doi: 10.1136/rmdopen-2016-000249. PMID: 27486526; PMCID: PMC4947732.
50. Silverman S, Curtis J, Saag K, et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015 Jan;26(1):419-20. doi: 10.1007/s00198-014-2883-2. Epub 2014 Sep 26. PMID: 25257932; PMCID: PMC4873770.
51. Steed L, Sohanpal R, Todd A, et al. Community pharmacy interventions for health promotion: effects on professional practice and health outcomes. Cochrane Database Syst Rev. 2019 Dec 6;12(12):CD011207. doi: 10.1002/14651858.CD011207.pub2. PMID: 31808563; PMCID: PMC6896091.
52. McDonough RP, Doucette WR, Kumbera P, Klepser DG. An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health. 2005 Jan-Feb;8(1):24-31. doi: 10.1111/j.1524-4733.2005.04007.x. PMID: 15841891.
53. Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, Kerstens M, Hermus AR. A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur J Endocrinol. 2013 May 17;169(1):17-22. doi: 10.1530/EJE-12-1094. PMID: 23636446.
54. Hwang YG, Saag K. The Safety of Low-Dose Glucocorticoids in Rheumatic Diseases: Results from Observational Studies. Neuroimmunomodulation. 2015;22(1–2): 72-82. doi: 10.1159/000362727.
55. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: a meta-analysis. J Investig Med. 2008 Dec;56(8):1011-8. doi: 10.2310/JIM.0b013e31818e82d7. PMID: 19050459.
56. van Staa TP, Leufkens HG, Cooper C. The epidemio–logy of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87. doi: 10.1007/s001980200108. PMID: 12378366.
57. Adami G, Fassio A, Bertelle D, Benini C, Gatti D, Rossini M. Impact of glucocorticoid dosing and anti-osteoporotic treatment on bone health in patients with inflammatory rheumatic musculoskeletal diseases: a longitudinal cohort study [abstract]. Arthritis Rheumatol. 2022;74 (suppl 9). Accessed 2024.06.30. https://acrabstracts.org/abstract/impact-of-glucocorticoid-dosing-and-anti-osteoporotic-treatment-on-bone-health-in-patients-with-inflammatory-rheumatic-musculoskeletal-diseases-a-longitudinal-cohort-study.
58. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med. 2005;257(4):374-384. doi: 10.1111/j.1365-2796.2005.01467.x.
59. Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR. Glucocorticoid exposure and fracture risk in a cohort of us patients with selected conditions. J Bone Miner Res. 2018 Oct;33(10):1881-1888. doi: 10.1002/jbmr.3523. Epub 2018 Aug 22. PMID: 29924418.
60. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809-816. doi: 10.1007/s00198-010-1524-7.
61. Lems WF, Baak MME, van Tuyl LHD, et al. One-year effects of glucocorticoids on bone density: a meta-ana–lysis in cohorts on high and low dose therapy. RMD Open 2016;2:e000313. doi: 10.1136/rmdopen-2016- 000313.
62. Peng S, Tan C, Du L, Niu Y, Liu X, Wang R. Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2023 Aug 17;23(1):304. doi: 10.1186/s12890-023-02602-5. PMID: 37592316; PMCID: PMC10436625.
63. Egeberg A, Schwarz P, Harsløf T, et al. Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures. JAMA Dermatol. 2021 Mar 1;157(3):275-282. doi: 10.1001/jamadermatol.2020.4968. PMID: 33471030; PMCID: PMC7970335.
64. Hsieh BJ, Shen D, Chan TC, Cho YT, Tang CH, Chu CY. Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: A nationwide case-control study. J Eur Acad Dermatol Venereol. 2024 Jul;38(7):1347-1356. doi: 10.1111/jdv.19697. Epub 2023 Dec 20. PMID: 38115791.
65. David J, Benes G, Dasa V, et al. Parenteral Corticosteroids After Fragility Fracture Increases the Odds of a Repeat Fracture. Journal of Orthopaedic Experience & Innovation. 2023;4(2). doi: 10.60118/001c.68314.
66. Zavatta G, Clarke BL. Glucocorticoid- and Transplantation-Induced Osteoporosis. Endocrinol Metab Clin North Am. 2021 Jun;50(2):251-273. doi: 10.1016/j.ecl.2021.03.002. PMID: 34023042.
67. Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239-3249. doi: 10.1007/s00198-016-3646-z.
68. Iki M, Fujimori K, Nakatoh S, et al. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int. 2024 Jan 24. doi: 10.1007/s00198-024-07023-6.
69. Golovach I. Controversies related to determination of the glucocorticoid-induced osteoporosis intervention threshold: who are the patients? Pain. Joints. Spine. 2019;9(4):237-250. doi: 10.22141/2224-1507.9.4.2019.191923. (in Ukrainian).
70. Kanis JA, Johansson H, Oden A, et al. A meta-ana–lysis of prior corticosteroid use and fracture risk. J Bone Mi–ner Res. 2004 Jun;19(6):893-9. doi: 10.1359/JBMR.040134. Epub 2004 Jan 27. PMID: 15125788.
71. Blavnsfeldt AG, de Thurah A, et al. The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized, controlled trials. Bone. 2018 Sep;114:172-180. doi: 10.1016/j.bone.2018.06.008. Epub 2018 Jun 18. PMID: 29913256.
72. Boers M, Hartman L, Opris-Belinski D, et al.; –GLORIA Trial consortium. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled –GLORIA trial. Ann Rheum Dis. 2022 Jul;81(7):925-936. doi: 10.1136/annrheumdis-2021-221957. Epub 2022 May 31. PMID: 35641125; PMCID: PMC9209692.
73. Wang Y, Zhao R, Gu Z, Dong C, Guo G, Li L. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2020 Aug;31(8):1401-1409. doi: 10.1007/s00198-020-05360-w. Epub 2020 Apr 14. PMID: 32291467.
74. Ozen G, Kamen DL, Mikuls TR, England BR, Wolfe F, Michaud K. Trends and determinants of osteoporosis treatment and screening in patients with rheumatoid arthritis compared to osteoarthritis. Arthritis Care Res (Hoboken). 2018 May;70(5):713-723. doi: 10.1002/acr.23331. Epub 2018 Mar 11. PMID: 28771973; PMCID: PMC5797515.
75. Kanis JA, Johnell O, De Laet C, et al. A meta-ana–lysis of previous fracture and subsequent fracture risk. Bone. 2004 Aug;35(2):375-82. doi: 10.1016/j.bone.2004.03.024.
76. Johnson NA, Stirling ER, Divall P, Thompson JR, Ullah AS, Dias JJ. Risk of hip fracture following a wrist fracture-A meta-analysis. Injury. 2017 Feb;48(2):399-405. doi: 10.1016/j.injury.2016.11.002.
77. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004 Nov;35(5):1029-37. doi: 10.1016/j.bone.2004.06.017.
78. De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005 Nov;16(11):1330-8. doi: 10.1007/s00198-005- 1863-y.
79. Kaze AD, Rosen HN, Paik JM. A meta-analysis of the association between body mass index and risk of vertebral fracture. Osteoporos Int. 2018 Jan;29(1):31-39. doi: 10.1007/s00198-017-4294-7.
80. Shen GS, Li Y, Zhao G, et al. Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury. 2015 Jul;46(7):1333-40. doi: 10.1016/j.injury.2015.04.008.
81. Cheraghi Z, Doosti-Irani A, Almasi-Hashiani A, et al. The effect of alcohol on osteoporosis: A systematic review and meta-analysis. Drug Alcohol Depend. 2019 Apr 1;197:197-202. doi: 10.1016/j.drugalcdep.2019.01.025.
82. Ke Y, Hu H, Zhang J, et al. Alcohol Consumption and Risk of Fractures: A Systematic Review and Dose- Response Meta-Analysis of Prospective Cohort Studies. Adv Nutr. 2023 Jul;14(4):599-611. doi: 10.1016/j.advnut.2023.03.008.
83. Asoudeh F, Salari-Moghaddam A, Larijani B, Esmaillzadeh A. A systematic review and meta-analysis of prospective cohort studies on the association between alcohol intake and risk of fracture. Crit Rev Food Sci Nutr. 2022;62(20):5623-5637. doi: 10.1080/10408398.2021.1888691.
84. Anagnostis P, Siolos P, Gkekas NK, et al. Association between age at menopause and fracture risk: a systematic review and meta-analysis. Endocrine. 2019 Feb;63(2):213- 224. doi: 10.1007/s12020-018-1746-6.
85. Vandenput L, Johansson H, McCloskey EV, et al. A meta-analysis of previous falls and subsequent fracture risk in cohort studies. Osteoporos Int. 2024 Mar;35(3):469-494. doi: 10.1007/s00198-023-07012-1. Epub 2024 Jan 17. PMID: 38228807.
86. Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P. Bone fracture risk in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2017 Sep;96(36):e6983. doi: 10.1097/MD.0000000000006983.
87. Jin S, Hsieh E, Peng L, et al. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018 Jun;29(6):1263-1275. doi: 10.1007/s00198-018-4473-1.
88. Chen B, Cheng G, Wang H, Feng Y. Increased risk of vertebral fracture in patients with rheumatoid arthritis: A meta-analysis. Medicine (Baltimore). 2016 Nov;95(45):e5262. doi: 10.1097/MD.0000000000005262.
89. Starup-Linde J, Hygum K, Harsløf T, Langdahl B. Type 1 Diabetes and Bone Fragility: Links and Risks. Diabetes Metab Syndr Obes. 2019 Dec 3;12:2539-2547. doi: 10.2147/DMSO.S191091.
90. De Araújo IM, Moreira MLM, de Paula FJA. Diabetes and bone. Arch Endocrinol Metab. 2022 Nov 11;66(5):633-641. doi: 10.20945/2359-3997000000552.
91. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012 Nov;27(11):2231-7. doi: 10.1002/jbmr.1759. Epub 2012 Sep 28. Erratum in: J Bone Miner Res. 2017 Nov;32(11):2319.
92. van Bodegraven AA, Bravenboer N. Perspective on skeletal health in inflammatory bowel disease. Osteoporos Int. 2020 Apr;31(4):637-646. doi: 10.1007/s00198-019- 05234-w.
93. Arvind C, Ragul B, Sudha M. Prevalence of premenopausal osteoporosis in hypothyroid patients. Int J Adv Med. 2020;7(3):431-434. doi: 10.18203/2349-3933. ijam20200653.
94. Mortensen SJ, Mohamadi A, Wright CL, et al. Medications as a Risk Factor for Fragility Hip Fractures: A Systematic Review and Meta-analysis. Calcif Tissue Int. 2020 Jul;107(1):1-9. doi: 10.1007/s00223-020-00688-1.
95. Kanis JA, Johansson H, Harvey NC, McCloskey EV. A brief history of FRAX. Arch Osteoporos. 2018 Oct 31;13(1):118. doi: 10.1007/s11657-018-0510-0.
96. Chen JF, Yu SF, Chiu WC, et al. Development and Comparison of Treatment Decision Tools for Glucocorticoid-Induced Osteoporosis. Diagnostics (Basel). 2024 Feb 19;14(4):452. doi: 10.3390/diagnostics14040452. PMID: 38396490; PMCID: PMC10887529.
97. Leib ES, Saag KG, Adachi JD, et al. FRAX(®) Position Development Conference Members. Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). J Clin Densitom. 2011 Jul-Sep;14(3):212-9. doi: 10.1016/j.jocd.2011.05.014. PMID: 21810527.
98. Povoroznyuk V, Grуgorieva N, Kanis J, McCloskey E, Johansson H. Ukrainian Version of FRAX: from creation to validation. Pain. Joints. Spine. 2021;(3):5-14. doi: 10.22141/2224-1507.3.23.2016.85000.
99. Povoroznyuk V, Grygorieva N, Johansson H, et al. FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. J Osteoporos. 2021 Jun 10;2021:2043479. doi: 10.1155/2021/2043479.
100. Grygorieva N, Kovalenko V, Коrzh М, et al. Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis. Pain. Joints. Spine. 2023:13(3):128-154. doi: 10.22141/pjs.13.3.2023.378.
101. Mok CC, Ho LY, Tse SM, et al. POS0171 Underestimation of the fracture risk by the FRAX formula in chro–nic glucocorticoid users: A 10-year longitudinal validation study. Annals of the Rheumatic Diseases. 2021;80:298. doi: 10.1136/annrheumdis-2021-eular.3400.
102. Xu Q, Ou X, Li J. The risk of falls among the aging population: A systematic review and meta-analysis. Front Public Health. 2022 Oct 17;10:902599. doi: 10.3389/fpubh.2022.902599. PMID: 36324472; PMCID: PMC9618649.
103. Montero-Odasso M, van der Velde N, Martin FC, et al., the Task Force on Global Guidelines for Falls in Older Adults. World guidelines for falls prevention and management for older adults: a global initiative. Age and Ageing. 2022;51(9):afac205. doi: 10.1093/ageing/afac205.
104. Hacıdursunoğlu Erbaş D, Çınar F, Eti Aslan F. Elderly patients and falls: a systematic review and meta-analysis. Aging Clin Exp Res. 2021 Nov;33(11):2953-2966. doi: 10.1007/s40520-021-01843-w. Epub 2021 Apr 16. PMID: 33864235.
105. James SL, Lucchesi LR, Bisignano C, et al. The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Inj Prev. 2020 Oct;26(Supp 1):i3-i11. doi: 10.1136/injuryprev-2019-043286. Epub 2020 Jan 15. PMID: 31941758; PMCID: PMC7571347.
106. Bodine SC, Furlow JD. Glucocorticoids and Ske–letal Muscle. Adv Exp Med Biol. 2015;872:145-76. doi: 10.1007/978-1-4939-2895-8_7. PMID: 26215994.
107. Webster JM, Fenton CG, Langen R, Hardy RS. Exploring the Interface between Inflammatory and Therapeutic Glucocorticoid Induced Bone and Muscle Loss. International Journal of Molecular Sciences. 2019;20(22):5768. doi: 10.3390/ijms20225768.
108. Harvey NC, Odén A, Orwoll E, et al. Jodi Lapidus, Timothy Kwok, Magnus K Karlsson, Björn E Rosengren, Östen Ljunggren, Cyrus Cooper, Eugene McCloskey, John A Kanis et al. Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS). 2018 March;33(3):510-516. doi: 10.1002/jbmr.3331.
109. Lusardi MM, Fritz S, Middleton A, et al. Determining Risk of Falls in Community Dwelling Older Adults: A Systematic Review and Meta-analysis Using Posttest Probability. J Geriatr Phys Ther. 2017 Jan/Mar;40(1):1-36. doi: 10.1519/JPT.0000000000000099. PMID: 27537070; –PMCID: PMC5158094.
110. Park SH. Tools for assessing fall risk in the elderly: a systematic review and meta-analysis. Aging Clin Exp Res. 2018 Jan;30(1):1-16. doi: 10.1007/s40520-017-0749-0. Epub 2017 Apr 3. PMID: 28374345.
111. Murayama A, Higuchi D, Saida K, Tanaka S, Shinohara T. Fall risk prediction for community-dwelling older adults: analysis of assessment scale and evaluation items without actual measurement. Int J Environ Res Public Health. 2024 Feb 14;21(2):224. doi: 10.3390/ijerph21020224. PMID: 38397713; PMCID: PMC10888445.
112. Miranda-Cantellops N, Tiu TK. Berg Balance Tes–ting. [Updated 2023 Feb 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574518.
113. Official Positions 2023 — ISCD. Available from: https://iscd.org/official-positions-2023.
114. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003 Nov;48(11):3224-9. doi: 10.1002/art.11283.
115. Larroudéd MS, Sommae LF, Giacoiaf E, et al. Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy. Reumatología Clínica. 2023;19(5):279-284. doi: 10.1016/j.reuma.2022.10.002. https://www.reumatologiaclinica.org/es-threshold-based-on-bone-mineral-articulo-S1699258X22002297.
116. Lee TH, Song YJ, Kim H, Sung YK, Cho SK. Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines. J Bone Metab. 2020 Nov;27(4):247-259. doi: 10.11005/jbm.2020.27.4.247. Epub 2020 Nov 30. PMID: 33317228; PMCID: PMC7746480.
117. Brance ML, Larroudé MS, Somma LF, et al. Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy. Reumatol Clin (Engl Ed). 2023 May;19(5):279-284. doi: 10.1016/j.reumae.2022.10.002.
118. Cho SK, Sung YK. Update on Glucocorticoid Induced Osteoporosis. Endocrinol Metab (Seoul). 2021 Jun;36(3):536-543. doi: 10.3803/EnM.2021.1021. Epub 2021 Jun 1. PMID: 34107602; PMCID: PMC8258322.
119. Lekamwasam S, Adachi JD, Agnusdei D, et al.; Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257-76. doi: 10.1007/s00198-012-1958-1. Epub 2012 Mar 21. PMID: 22434203.
120. Borges JLC, de M Miranda IS, Lewiecki EM. The Clinical Utility of Vertebral Fracture Assessment in Predicting Fractures. J Clin Densitom. 2017 Jul-Sep;20(3):304-308. doi: 10.1016/j.jocd.2017.06.016. Epub 2017 Jul 18. PMID: 28729044.
121. Cai S, Yu H, Li Y, et al. Bone mineral density measurement combined with vertebral fracture assessment increases diagnosis of osteoporosis in postmenopausal women. Skeletal Radiol. 2020 Feb;49(2):273-280. doi: 10.1007/s00256-019-03280-3. Epub 2019 Jul 27. PMID: 31352490.
122. Ginther JP, Ginther AW, Brodersen LD. Adding VFA to DXA identifies fracture risk in a way not duplicated by other measures. Endocr Pract. 2017 Dec;23(12):1375-1378. doi: 10.4158/EP161714.OR. Epub 2017 Oct 11. PMID: 29019717.
123. Borges JLC, Sousa da Silva M, et al. Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. J Clin Densitom. 2019 Oct-Dec;22(4):484-488. doi: 10.1016/j.jocd.2019.07.005. Epub 2019 Jul 10. PMID: 31375350.
124. Kaloudis E-Th. Trabecular bone score for the evaluation of fracture risk: A literature review. JRPMS. December 2022;6(4): doi: 10.22540/JRPMS-06-121.
125. Boyadzhieva Z, Palmowski A, Buttgereit F, Hoff P. Trabecular bone score in rheumatology: Are there benefits in comparison to bone densitometry alone? Z Rheumatol. 2023 Oct;82(8):672-677. German. doi: 10.1007/s00393-023-01407-5. Epub 2023 Aug 30. PMID: 37646845.
126. Warzecha M, Czerwiński E, Amarowicz J, Berwecka M. Trabecular Bone Score (TBS) in Clinical Practice — Rewiev. Ortop Traumatol Rehabil. 2018 Oct 31;20(5):347-359. doi: 10.5604/01.3001.0012.7281. PMID: 30648658.
127. Halupczok-Żyła J, Gojny Ł, Bolanowski M. Trabe–cular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders. Endokrynol Pol. 2019;70(4):350-356. doi: 10.5603/EP.a2019.0022. PMID: 31489959.
128. Sandru F, Carsote M, Dumitrascu MC, Albu SE, Valea A. Glucocorticoids and Trabecular Bone Score. J Med Life. 2020 Oct-Dec;13(4):449-453. doi: 10.25122/jml-2019-0131. PMID: 33456590; PMCID: PMC7803323.
129. McCloskey EV, Odén A, Harvey NC et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016 May;31(5):940-8. doi: 10.1002/jbmr.2734. Epub 2015 Nov 19. PMID: 26498132.
130. Hans D, Šteňová E, Lamy O. The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice. Curr Osteoporos Rep. 2017 Dec;15(6):521-531. doi: 10.1007/s11914-017-0410-z. PMID: 28988401.
131. Al-Hashimi L, Klotsche J, Ohrndorf S, Gaber T, Hoff P. Trabecular Bone Score Significantly Influences Treatment Decisions in Secondary Osteoporosis. J Clin Med. 2023 Jun 20;12(12):4147. doi: 10.3390/jcm12124147. PMID: 37373840; PMCID: PMC10299520.
132. Nowakowska-Płaza A, Wroński J, Sudoł-Szopińska I, Głuszko P. Clinical Utility of Trabecular Bone Score (TBS) in Fracture Risk Assessment of Patients with Rheumatic Diseases Treated with Glucocorticoids. Horm Metab Res. 2021 Aug;53(8):499-503. doi: 10.1055/a-1528-7261. Epub 2021 Aug 12. PMID: 34384106.
133. Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology (Oxford). 2020 Jul 1;59(7):1574-1580. doi: 10.1093/rheumatology/kez464. PMID: 31628810.
134. Lee KA, Kim J, Kim HJ, Kim HS. Discriminative ability of trabecular bone score over bone mineral density for vertebral and fragility fracture in patients treated with long-term and low-dose glucocorticoid. Int J Rheum Dis. 2021 Aug;24(8):1053-1060. doi: 10.1111/1756-185X.14164. Epub 2021 Jun 29. PMID: 34184827.
135. Palomo T, Muszkat P, Weiler FG, Dreyer P, Brandão CMA, Silva BC. Update on trabecular bone score. Arch Endocrinol Metab. 2022 Nov 11;66(5):694-706. doi: 10.20945/2359-3997000000559. PMID: 36382759; –PMCID: PMC10118821.
136. Ruangnopparut R, Charoensri S, Sribenjalak D, Theerakulpisut D, Pongchaiyakul C. Trabecular Bone Score Improves Fracture Risk Discrimination in Postmenopausal Rheumatoid Arthritis Patients Receiving Glucocorticoids. Int J Gen Med. 2024 Jan 26;17:287-295. doi: 10.2147/IJGM.S448659.
137. Corrado A, Rotondo C, Mele A, et al. Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis Res Ther. 2021 Jul 6;23(1):180. doi: 10.1186/s13075-021-02562-3. PMID: 34229744; PMCID: PMC8261978.
138. Rymuza J, Pelewicz K, Przedlacki J, Miśkiewicz P. Therapy with intravenous methylprednisolone pulses is associated with loss of bone microarchitecture in Trabecular Bone Score — assessment among patients with moderate-to-severe Graves’ Orbitopathy: A Pilot Study. Front Endocrinol (Lausanne). 2022 Jul 14;13:893600. doi: 10.3389/fendo.2022.893600. PMID: 35909547; PMCID: PMC9331277.
139. Chuang MH, Chuang TL, Koo M, Wang YF. Trabecular Bone Score Reflects Trabecular Microarchitecture Deterioration and Fragility Fracture in Female Adult Patients Receiving Glucocorticoid Therapy: A Pre-Post Controlled Study. Biomed Res Int. 2017;2017:4210217. doi: 10.1155/2017/4210217. Epub 2017 Jan 3. PMID: 28127556; PMCID: PMC5239831.
140. Shevroja E, Reginster JY, Lamy O, et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int. 2023 Sep;34(9):1501-1529. doi: 10.1007/s00198-023-06817-4. Epub 2023 Jul 1. PMID: 37393412; PMCID: PMC10427549.
141. Mortensen SJ, Beeram I, Florance J, et al. Modifiable lifestyle factors associated with fragility hip fracture: a systematic review and meta-analysis. J Bone Miner Metab. 2021 Sep;39(5):893-902. doi: 10.1007/s00774-021-01230-5.
142. Clemson L, Stark S, Pighills AC, et al. Environmental interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2023 Mar 10;3(3):CD013258. doi: 10.1002/14651858.CD013258. pub2.
143. Caristia S, Campani D, Cannici C, et al. Physical exercise and fall prevention: A systematic review and meta-analysis of experimental studies included in Cochrane reviews. Geriatr Nurs. 2021 Nov-Dec;42(6):1275-1286. doi: 10.1016/j.gerinurse.2021.06.001. Epub 2021 Sep 21. PMID: 34555570.
144. Kast S, Shojaa M, Kohl M, et al. Effects of different exercise intensity on bone mineral density in adults: a comparative systematic review and meta-analysis. Osteoporos Int. 2022 Aug;33(8):1643-1657. doi: 10.1007/s00198-022- 06329-7.
145. Hoffmann I, Kohl M, von Stengel S, et al. Exercise and the prevention of major osteoporotic fractures in adults: a systematic review and meta-analysis with special emphasis on intensity progression and study duration. Osteoporos Int. 2023 Jan;34(1):15-28. doi: 10.1007/s00198-022-06592-8.
146. Schinzel E, Kast S, Kohl M, et al. The effect of aquatic exercise on bone mineral density in older adults. A systematic review and meta-analysis. Front Physiol. 2023 Mar 13;14:1135663. doi: 10.3389/fphys.2023.1135663.
147. Pinheiro MB, Oliveira J, Bauman A, et al. Evidence on physical activity and osteoporosis prevention for people aged 65 + years: a systematic review to inform the WHO guidelines on physical activity and sedentary behavior. Int J Behav Nutr Phys Act. 2020;17:150. doi: 10.1186/s12966-020-01040-4.
148. Shojaa M, von Stengel S, Kohl M, Schoene D, Kemmler W. Effects of dynamic resistance exercise on bone mineral density in postmenopausal women: a systematic review and meta-analysis with special emphasis on exercise parameters. Osteoporos Int. 2020 Aug;31(8):1427-1444. doi: 10.1007/s00198-020-05441-w.
149. Kast S, Jakob F, Kohl M, et al. Exercise effects on glucocorticoid-induced bone loss in adults: a syste–matic review and meta-analysis. Rheumatol Adv Pract. 2023 Feb 6;7(1):rkad019. doi: 10.1093/rap/rkad019. PMID: 36844918; PMCID: PMC9945849.
150. Esteves GP, Mazzolani BC, Smaira FI, et al. Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy. Rheumatol Adv Pract. 2022 Apr 21;6(2):rkac029. doi: 10.1093/rap/rkac029. PMID: 35539442; PMCID: PMC9080102.
151. Golovach IYu. Recommendations for nutrition (diet) for patients on glucocorticoid therapy. Health of Ukraine 21 stories. 2023;18(554):21-22. (in Ukrainian).
152. Fabiani R, Naldini G, Chiavarini M. Dietary patterns in relation to low bone mineral density and fracture risk: a systematic review and meta-analysis. Advances in nutrition (Bethesda, Md). 2019;10:219-236. doi: 10.1093/advances/nmy073.
153. Iguacel I, Miguel-Berges ML, Gómez-Bruton A, Moreno LA, Julián C. Veganism, vegetarianism, bone mineral density, and fracture risk: a systematic review and meta-analysis. Nutr Rev. 2019;77:1-18. doi: 10.1093/nutrit/nuy045.
154. Golovach IYu. Contemporary Strategies for Prevention and Treatment of Osteoporosis: Role of Calcium and Vitamin D. Family Medicine. 2020;4(90):28-31. doi: 10.30841/2307-5112.4.2020.217351. (in Ukrainian).
155. Grygorieva N, Povoroznyuk V, Romanenko M, Synieok L. Calcium intake in an adult Ukrainian population. Arch Osteoporos. 2020 Feb 23;15(1):23. doi: 10.1007/s11657-020-0712-0. PMID: 32090299.
156. Grygorieva N, Solonenko T, Musiienko A. Vitamin D deficiency during the COVID-19 pandemic and war in Ukraine. Pain. Joints. Spine. 2023;13(1);7-14. doi: 10.22141/pjs.13.1.2023.352. (in Ukrainian).
157. Weaver CM, Alexander DD, Boushey CJ, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016 Jan;27(1):367-76. doi: 10.1007/s00198-015-3386-5. Epub 2015 Oct 28. Erratum in: Osteoporos Int. 2016 Aug;27(8):2643-6.
158. Yao P, Bennett D, Mafham M, et al. Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019 Dec 2;2(12):e1917789. doi: 10.1001/jamanetworkopen.2019.17789.
159. Liu C, Kuang X, Li K, Guo X, Deng Q, Li D. Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Food Funct. 2020 Dec 1;11(12):10817-10827. doi: 10.1039/ d0fo00787k; Zhao JG, Zeng XT, Wang J, Liu L. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. JAMA. 2017 Dec 26;318(24):2466-2482. doi: 10.1001/jama.2017.19344.
160. Deng J, Silver Z, Huang E, Zheng E, Kavanagh K, Panicker J. The Effect of Calcium and Vitamin D Compounds on Bone Mineral Density in Patients Undergoing Glucocorticoid Therapies: A Network Meta-Analysis. Clin Rheumatol. 2021;40:725-34. doi: 10.1007/s10067-020-05294-y.
161. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000;1998(2):CD000952. doi: 10.1002/14651858.CD000952. PMID: 10796394; PMCID: PMC7046131.
162. Order of the Ministry of Health of Ukraine No 1073 dated September 3, 2017. On the approval of the norms of physiological needs of the population of Ukraine in basic food substances and energy. Available from: https://zakon. rada.gov.ua/laws/show/z1206-17#Text.
163. Grygorieva N, Tronko M, Kovalenko V, et al. Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement. Pain. Joints. Spine. 2023;13(2):60-76. doi: 10.22141/pjs.13.2.2023.368.
164. Sugimoto T, Matsumoto T, Hosoi T, et al. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status. J Bone Miner Metab. 2020 Nov;38(6):848-858. doi: 10.1007/s00774-020-01119-9.
165. Suzuki T, Nakamura Y, Kato H. Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis. Ther Clin Risk Manag. 2018 Dec 18;15:15-22. doi: 10.2147/ TCRM.S182858.
166. Lu K, Shi Q, Gong YQ, Li C. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Front Endocrinol (Lausanne). 2022 Oct 10;13:991913. doi: 10.3389/ fendo.2022.991913.
167. Shams-White MM, Chung M, Du M, et al. Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation. Am J Clin Nutr. 2017 Jun;105(6):1528-1543. doi: 10.3945/ ajcn.116.145110.
168. Wallace TC, Frankenfeld CL. Dietary Protein Intake above the Current RDA and Bone Health: A Systematic Review and Meta-Analysis. J Am Coll Nutr. 2017 Aug;36(6):481-496. doi: 10.1080/07315724.2017.1322924.
169. Groenendijk I, den Boeft L, van Loon LJC, de Groot L. High versus low dietary protein intake and bone health in older adults: a systematic review and meta-ana–lysis. Comput Struct Biotechnol J. 2019;17:1101-1112. doi: 10.1016/j.csbj.2019.07.005.
170. Darling AL, Manders RJF, Sahni S, Zhu K, Hewitt CE, Prince RL, Millward DJ, Lanham-New SA. Dietary protein and bone health across the life-course: an updated systematic review and meta-analysis over 40 years. Osteoporos Int. 2019;30:741-761. doi: 10.1007/s00198-019-04933-8.
171. Wu AM, Sun XL, Lv QB, et al. The relationship between dietary protein consumption and risk of fracture: a subgroup and dose-response meta-analysis of prospective cohort studies. Sci Rep. 2015 Mar 16;5:9151. doi: 10.1038/ srep09151.
172. Rizzoli R, Biver E, Bonjour JP, et al. Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporos Int. 2018 Sep;29(9):1933- 1948. doi: 10.1007/s00198-018-4534-5.
173. Deng J, Silver Z, Huang E, et al. Pharmacological Prevention of Fractures in Patients Undergoing Glucocorticoid Therapies: A Systematic Review and Network Meta-Analysis. Rheumatol (Oxford). 2021;60:649-57. doi: 10.1093/rheumatology/keaa228.
174. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018 Jul;61(1):7-16. doi: 10.1007/s12020-018-1588-2.
175. Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. Osteoporos Int. 2016 Jun;27(6):1989-98. doi: 10.1007/s00198-015-3476-4.
176. Anastasilaki E, Paccou J, Gkastaris K, Anastasilakis AD. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management. Hormones (Athens). 2023 Dec;22(4):611-622. doi: 10.1007/s42000-023-00491-1. Epub 2023 Sep 27. PMID: 37755658.
177. Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic di–sease. Ann Rheum Dis. 2022 Aug 11;81(9):1313-1322. doi: 10.1136/annrheumdis-2022-222339. PMID: 35680387; PMCID: PMC9380479.
178. Compston JE. Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis. Eur J Endocrinol. 2023 Mar 2;188(3):R46-R55. doi: 10.1093/ejendo/lvad029. PMID: 36880157.
179. Raterman HG, Bultink IEM, Lems WF. Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6.
180. Chiodini I, Merlotti D, Falchetti A, Gennari L. Treatment options for glucocorticoid-induced osteoporosis. Expert Opin Pharmacother. 2020 Apr;21(6):721-732. doi: 10.1080/14656566.2020.1721467. Epub 2020 Jan 31. PMID: 32004105.
181. Wong SPY, Mok CC. Management of glucocorticoid-related osteoporotic vertebral fracture. Osteoporos Sarcopenia. 2020 Mar;6(1):1-7. doi: 10.1016/j.afos.2020.02.002. Epub 2020 Mar 3. PMID: 32226826; PMCID: PMC7093682.
182. Iki M, Fujimori K, Nakatoh S, et al. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. Bone. 2023 Jan;166:116605. doi: 10.1016/j.bone.2022.116605.
183. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292-9. doi: 10.1056/nejm199807303390502.
184. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol. 2009 Aug;36(8):1705-14. doi: 10.3899/jrheum.081207.
185. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001 Jan;44(1):202-11. doi: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W.
186. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999 Nov;42(11):2309-18. doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K.
187. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a rando–mized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000 Jun;15(6):1006-13. doi: 10.1359/jbmr.2000.15.6.1006.
188. Shin K, Park SH, Park W, et al. Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther. 2017 Feb;39(2):268-78.e2. doi: 10.1016/j.clinthera.2017.01.008.
189. Reid DM, Devogelaer JP, Saag K, et al. Zoledro–nic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/s0140-6736(09)60250-6.
190. Allen CS, Yeung JH, Vandermeer B, Homik J. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10(10):CD001347. doi: 10.1002/14651858.CD001347.pub2. PMID: 27706804; PMCID: PMC6461188.
191. Coskun Benlidayi I. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2018 Nov;38(11):1975-1984. doi: 10.1007/s00296-018-4106-1. Epub 2018 Jul 17. PMID: 30019224.
192. Ishida T, Yoshida S, Fujiki Y, Hata K, Kotani T, Takeuchi T. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study. Arch Osteoporos. 2021 Feb 23;16(1):39. doi: 10.1007/s11657-021-00899-5. PMID: 33624165.
193. Iwamoto N, Okamoto M, Tsuji S, et al. Denosu–mab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. J Bone Miner Metab. 2019 May;37(3):554-562. doi: 10.1007/s00774-018-0955-7. Epub 2018 Sep 5. PMID: 30187273.
194. Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019 Aug 14;13:2843-2852. doi: 10.2147/DDDT.S148654. PMID: 31616133; PMCID: PMC6698580.
195. Jiang L, Dong J, Wei J, Liu L. Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2022 Nov 29;23(1):1027. doi: 10.1186/s12891-022-05997-0. PMID: 36447169; PMCID: PMC9706902.
196. Zhu Linlin, Jiang Xinyan MS, Sun Yuhong, Shu Wenhuan. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of rando–mized controlled trials. Menopause. 2016 April;23(4):461-470. doi: 10.1097/GME.0000000000000519.
197. Migliorini F, Colarossi G, Eschweiler J, Oliva F, Driessen A, Maffulli N, Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis, British Medical Bulletin. 2022;143:46-56. doi: 10.1093/bmb/ldac017.
198. Liu Z, Zhang M, Shen Z, Ke J, Zhang D, Yin F. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials. PLoS One. 2020 Dec 16;15(12):e0243851. doi: 10.1371/journal.pone.0243851.
199. Dong B, Zhou Y, Wang J, et al. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Ana–lysis of Randomized Controlled Trials. Horm Metab Res. 2023 Apr;55(4):236-244. doi: 10.1055/a-2015-1747. Epub 2023 Jan 18. PMID: 36652960.
200. Yuan C, Liang Y, Zhu K, Xie W. Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Jun 22;18(1):447. doi: 10.1186/s13018-023-03920-4. PMID: 37349750; PMCID: PMC10286508.
201. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig. 2019 Sep 20;40(2):/j/hmbci.2019.40.issue-2/hmbci-2019-0021/hmbci-2019-0021.xml. doi: 10.1515/hmbci-2019-0021. PMID: 31539355.
202. de Campos WG, Araújo R, Teixeira V, Gomes PS, Lemos CA. Does the use of bisphosphonates du–ring pregnancy affect fetal outcomes? A systematic review. Eur J Clin Pharmacol. 2024 Aug;80(8):1121-1132. doi: 10.1007/s00228-024-03693-7. Epub 2024 May 1. PMID: 38691138.
203. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020 Jan;31(1):1-12. doi: 10.1007/s00198-019-05176-3.
204. Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022 Apr;34(4):695-714. doi: 10.1007/s40520-022- 02100-4.
205. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgaa048. doi: 10.1210/clinem/dgaa048.
206. Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2021 (SIGN publication no. 142). Available from: https://www.sign.ac.uk/ our-guidelines/management-of-osteoporosis-and-the-prevention-of-fragility-fractures. Accessed: 2024, 30.06.
207. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum. 2011 Feb;63(2):325-8. doi: 10.1002/art.30135.
208. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611. doi: 10.1016/j.ecl.2012.04.004. Epub 2012 May 23. PMID: 22877431; PMCID: PMC3417039.
209. Khan AA, Morrison A, Hanley DA, et al.; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405. PMID: 25414052.
210. Khow KS, Shibu P, Yu SC, Chehade MJ, Visvanathan R. Epidemiology and Postoperative Outcomes of Aty–pical Femoral Fractures in Older Adults: A Systematic Review. J Nutr Health Aging. 2017;21(1):83-91. doi: 10.1007/s12603-015-0652-3. PMID: 27999854.
211. Adler RA, El-Hajj Fuleihan G, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35. doi: 10.1002/jbmr.2708. Erratum in: J Bone Miner Res. 2016 Oct;31(10 ):1910. PMID: 26350171; PMCID: PMC4906542.
212. Meier C, Uebelhart B, Aubry-Rozier B et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly. 2017 Aug 16;147:w14484. doi: 10.4414/smw.2017.14484. PMID: 28871570.